Introduction {#S0001}
============

Colorectal cancer (CRC) is one of the most common cancers and the second cause of tumor-associated deaths worldwide.[@CIT0001] Because of lacking effective diagnostic biomarkers and therapeutic targets, patients with CRC progress rapidly.[@CIT0002] Additionally, due to high rate of metastasis, the mortality of CRC is very high. CRC patients with advanced stage display a rather low five-year survival rate.[@CIT0003] To date, the major therapeutic strategy is surgery combined with chemotherapy or radiotherapy. However, resistance to chemotherapy or radiotherapy is a major problem for most CRC patients.[@CIT0004] In order to improve the prognosis, it is urgently required to understand the molecular mechanism of CRC progression.

Long non-coding RNAs (lncRNA) are a family of noncoding RNAs with over 200 nucleotides in length which lack protein-coding potential.[@CIT0005] LncRNAs have been demonstrated to exert various functions in cancer, including regulating proliferation, invasion, survival and differentiation.[@CIT0006] Dysregulation of lncRNA has been observed in numerous human cancers.[@CIT0007] For example, lncRNA LUCAT1 is upregulated in ovarian cancer and promotes tumor growth and invasion via regulating miR-612/HOXA13 axis.[@CIT0008] LncRNA SNHG16 promotes proliferation, migration and invasion of bladder cancer cells through targeting miR-98/STAT3 signaling.[@CIT0009] In addition, lncRNA HULC is overexpressed in liver cancer and contributes to tumor growth and metastasis by elevating HMGA2 level through targeting miR-186.[@CIT0010] Thus, it is important to explore the correlation between lncRNA and CRC development.

LINC00173 (Chromosome 12: 116533422.116536513) in chro has been shown to regulate tumorigenesis of lung cancer and breast cancer.[@CIT0011],[@CIT0012] However, the exact role of LINC00173 in CRC is unclear. In our study, we showed that LINC00173 is overexpressed in CRC tissues and predicted poor prognosis. LINC00173 knockdown suppressed the proliferation, migration and invasion and increased the sensitivity of CRC cells to 5-fluorouracil (5-FU). Moreover, LINC00173 knockdown inhibited CRC growth in vivo. Mechanistically, we demonstrated that LINC00173 targeted miR-765/PLP2 axis. In conclusion, our findings reveal that LINC00173 exerts oncogenic roles and may be a potential therapeutic target for CRC treatment.

Materials and Methods {#S0002}
=====================

Human Samples {#S0002-S2001}
-------------

Human tissues and adjacent normal tissues (at least 5 cm away from the cancer tissues) were collected from The 2nd Affiliated Hospital of Harbin Medical University. At least 3 experienced pathologists confirmed all tissue specimens. All tissues were not treated with radiotherapy or chemotherapy before surgery. This study was approved by the Ethics Committee of The 2nd Affiliated Hospital of Harbin Medical University. Written informed consents were provided by patients. All experiments were performed in accordance with the Declaration of Helsinki.

Cell Culture {#S0002-S2002}
------------

Human colon immortalized cell line FHC and CRC cell lines were purchased from The Cell Bank of Type Culture Collection of the Chinese Academy of Sciences. All cells were cultured using DMEM medium (Gibco, USA) containing 10% FBS (Gibco, USA).

qRT-PCR {#S0002-S2003}
-------

Total RNA was isolated using TRIzol Reagent (Invitrogen; Thermo Fisher Scientific, Inc.) according to the manufacturer's protocol and used for cDNA synthesis through PrimeScript RT Reagent kit (Takara Bio, Inc.). qPCR was performed by using a SYBR Green PCR kit (Takara Bio, Inc.). U6 and GAPDH were utilized as internal controls. Relative expression was calculated according to the 2−^ΔΔCt^ method. Primer sequences were: LINC00173 (Forward, 5ʹ-GCCACCTTGCTCCGCTGTTC-3ʹ and reverse, 5ʹ-CCGAGGCTTGGAGAGGAGG-3ʹ), PLP2 (Forward, 5ʹ-ATTCATCAACTGGCCCTGGA-3ʹ and reverse, 5ʹ-AACGGGGAAGGTGACATAGG-3ʹ) and GAPDH (Forward, 5ʹ-ATGTTGCAACCGGGAAGGAA-3ʹ, reverse 5ʹ-AGGAAAAGCATCACCCGGAG-3ʹ).

Cell Transfection {#S0002-S2004}
-----------------

Short hairpin RNA (shRNA) targeting LINC00173 or PLP2 was utilized to knock down LINC00173 or PLP2. MiR-765 mimics, miR-765 inhibitors and negative controls were synthesized by GenePharma. Cell transfection was performed by using Lipofectamine^®^ 2000.

CCK8 Assay {#S0002-S2005}
----------

CCK8 assay was used to measure cell proliferation. Cells were seeded into the 96-well plates and cultured for 72 h. Then, 10 μL of CCK8 solution (Dojindo, Japan) was added into each well and incubated for 2h. Optical density (OD) values at 450 nm were determined by a microplate reader (Thermo Scientific, USA).

Wound-healing Assay {#S0002-S2006}
-------------------

Cells were plated into 6-well plates. When the each well was covered with a single layer of cells, a straight line was evenly created using a 200 μL pipette tip. After washed with PBS, the cells were grown at 37°C for 24 h. The wound area was observed under a microscope at 0 and 24 h.

Cell Migration and Invasion {#S0002-S2007}
---------------------------

Transwell assay was performed to test migration and invasion. Cells were seeded into the upper chamber filled with serum-free medium. The lower chamber was filled with DMEM medium supplemented with 10% FBS. After cultured for 24 h, migrated or invaded cells in the lower chamber were fixed with 4% of paraformaldehyde and stained with 0.1% crystal violet solution for 30 min. Then, cell photograph was captured using a light microscope.

Dual-luciferase Reporter Assay {#S0002-S2008}
------------------------------

Bioinformatics was used to predict the interaction between LINC00173 and miR-765 or between miR-765 and PLP2 through miRDB ([<http://mirdb.org/>]{.ul}) and TargetScan7 ([<http://www.targetscan.org/vert_71/>]{.ul}) tools. The wild-type (wt) or mutant (mut: 5ʹ-CUCCUCC-3ʹ mutated to 5ʹ-GAGGAGG-3ʹ) sequence of LINC00173 or PLP2 was inserted into pMIR-Report vector (Promega). For luciferase reporter assay HCT116 cells were co-transfected with luciferase vector and miR-765 mimics using Lipofectamine 2000. After 48 h, the luciferase activity was measured through the Dual Luciferase kit (Promega) and Renilla luciferase activity was used as control.

Tumor Xenograft Assay {#S0002-S2009}
---------------------

Six-week female BALB/c nude mice were from Beijing Huafu Kang Biological Technology Co., Ltd. 5 × 10^6^ HCT116 cells (sh-LINC00173 or sh-NC) were subcutaneously injected into the right flank of nude mice (n=5 for each group). The tumor volumes were measured every 1 week according to the formula: tumor volume (cm^3^) = (Leng×Width^2^)/2. After 5 weeks, tumor tissues (five tumor tissues per group from five mice) were harvested and weighed. The animal experiments were approved by The Ethics Committee of The 2nd Affiliated Hospital of Harbin Medical University. All animal operations were performed in accordance with the Animal Policy and Welfare Committee of The 2nd Affiliated Hospital of Harbin Medical University.

Statistical Analysis {#S0002-S2010}
--------------------

Statistical analysis was conducted using SPSS version 20.0 (IBM, Corp.) results are presented as the mean ± standard deviation. Differences between groups were analyzed using a Student's *t*-test or a one-way ANOVA. The Kaplan--Meier method was used to draw survival curve and the Log-rank test was used to determine statistical significance. P\<0.05 was considered as statistically significant.

Results {#S0003}
=======

LINC00173 is Upregulated in CRC {#S0003-S2001}
-------------------------------

To analyze LINC00173 expression, we collected 57 pairs of CRC tissues and corresponding normal tissues. Through qRT-PCR, we found that LINC00173 expression was significantly upregulated in CRC tissues ([Figure 1A](#F0001){ref-type="fig"}). Besides, LINC00173 expression was also elevated in CRC cell lines compared to FHC cells ([Figure 1B](#F0001){ref-type="fig"}). Then, the CRC tissues were divided into two subgroups (high or low expression by using the median value of LINC00173 as cut-off) according to LINC00173 expression values. The overall survival rate was analyzed through Kaplan--Meier curve. The result showed that LINC00173 low expression was associated with high survival rate ([Figure 1C](#F0001){ref-type="fig"}). Moreover, we found that LINC00173 high expression was associated with advanced TNM stage and lymph node metastasis ([Table 1](#T0001){ref-type="table"}).Table 1Association Between LINC00173 Expression and Clinical Characteristics in CRC Patients (n = 57)CharacteristicsLow (n=31)High (n=26)*P*-valueGender0.599 Male1712 Female1414Age (years)0.600 \<601313 ≥601813Lymph node metastasis0.003 Yes1019 No217TNM stage0.015 I/II1521 III/IV165 Figure 1LINC00173 is upregulated in CRC. (**A**) Relative expression of LINC00173 in 57 pairs of CRC tissues and adjacent normal tissues was analyzed by qRT-PCR. (**B**) Expression levels of LINC00173 in CRC cell lines were determined. (**C**) Survival curve was plotted by using Kaplan--Meier method and log-rank test according to LINC00173 expression value. \**P*\<0.05 and \*\**P*\<0.01.

LINC00173 Targets miR-765/PLP2 Signaling {#S0003-S2002}
----------------------------------------

We then determined the subcellular location of LINC00173 by qRT-PCR. We found that LINC00173 was mainly expressed in the cytoplasm of HCT116 cells ([Figure 2A](#F0002){ref-type="fig"}), suggesting it may be a competing endogenous RNA. Through bioinformatics analysis, we identified miR-765 as the most potential target miRNA ([Figure 2B](#F0002){ref-type="fig"}). Moreover, we also predicted the target of miR-765 and identified PLP2 ([Figure 2B](#F0002){ref-type="fig"}). To validate it, we performed luciferase reporter assay using HCT116 cells. As shown, miR-765 mimics markedly inhibited the activity of LINC00173-wt or PLP2-wt vectors ([Figure 2C](#F0002){ref-type="fig"} and [D](#F0002){ref-type="fig"}), demonstrating their interactions. qRT-PCR showed that LINC00173 knockdown led to increased expression of miR-765 ([Figure 2E](#F0002){ref-type="fig"}). And miR-765 mimics also suppressed the expression of PLP2 ([Figure 2F](#F0002){ref-type="fig"}). Moreover, we found that PLP2 expression was decreased after LINC00173 silencing and rescued after transfection of miR-765 inhibitors ([Figure 2G](#F0002){ref-type="fig"}), indicating that LINC00173 promotes PLP2 expression via sponging miR-765.Figure 2LINC00173 targets miR-765/PLP2 signaling. (**A**) The subcellular distribution of LINC00173 in HCT116 cells was explored. (**B**) Predicted binding sites among LINC00173, miR-765 and PLP2 were presented. miRDB and TargetScan7 were used for prediction. (**C** and **D**) Luciferase reporter assays were performed to validate the interaction between LINC00173 and miR-765 or between miR-765 and PLP2 in HCT116 cells. (**E**) LINC00173 knockdown promoted miR-765 expression. (**F**) qRT-PCR showed that miR-765 mimics inhibited PLP2 expression. (**G**) Relative expression of PLP2 was determined by qRT-PCR. \*\**P*\<0.01.

LINC00173/miR-765/PLP2 Axis Regulates the Proliferation, Migration, Invasion and Chemo-Resistance of CRC Cells {#S0003-S2003}
--------------------------------------------------------------------------------------------------------------

To further explore the potential roles of LINC00173/miR-765/PLP2 axis in CRC, we performed a series of experiments. We first measured the expression of PLP2 to confirm the success of transfection ([Figure 3A](#F0003){ref-type="fig"}). CCK8 assay showed that LINC00173 knockdown inhibited the proliferation of HCT116 and SW480 cells while miR-765 inhibitors reversed it ([Figure 3B](#F0003){ref-type="fig"}). Moreover, PLP2 knockdown further inhibited the proliferation of CRC cells transfected with sh-LINC00173 plus miR-765 inhibitors ([Figure 3B](#F0003){ref-type="fig"}), which was further validated by EdU assay ([Figure 3C](#F0003){ref-type="fig"}). Then, wound-healing assay was performed to test migration. As shown, in sh-LINC00173 or shLINC00173+miR-inhibitor+sh-PLP2 group the scratch wound closure capacity was obviously suppressed ([Figure 3D](#F0003){ref-type="fig"}). Similarly, we measured the effects of LINC00173/miR-765/PLP2 axis on metastasis by transwell assay. We found that LINC00173 knockdown inhibited migration and invasion while miR-765 inhibitors reversed it ([Figure 3E](#F0003){ref-type="fig"} and [F](#F0003){ref-type="fig"}). PLP2 depletion also further reversed it in CRC cells transfected with sh-LINC00173 plus miR-765 inhibitors ([Figure 3E](#F0003){ref-type="fig"} and [F](#F0003){ref-type="fig"}). To further investigate the effect of LINC00173/miR-765/PLP2 axis on chemo-resistance, we treated HCT116 and SW480 cells with 5-FU after transfection of indicated vectors. Interestingly, we also observed a similar trend as proliferation, migration and invasion ([Figure 3G](#F0003){ref-type="fig"}). Therefore, LINC00173 promotes the proliferation, migration, invasion and chemo-resistance of CRC cells through targeting miR-765/PLP2 axis.Figure 3LINC00173/miR-765/PLP2 axis regulates the proliferation, migration, invasion and chemo-resistance of CRC cells. (**A**) Relative expression of PLP2 was determined by qRT-PCR after transfection of indicated plasmids. (**B** and **C**) CCK8 and EdU assays were performed to detect the proliferation. (**D**) Cell migration was measured by wound-healing assay. (**E** and **F**) Transwell assay was performed to analyze cell migration and invasion. (**G**) The sensitivity to 5-FU of CRC cells was measured. \**P*\<0.05 and \*\**P*\<0.01.

LINC00173/miR-765/PLP2 Axis Affects CRC Growth in vivo {#S0003-S2004}
------------------------------------------------------

To further demonstrate their roles in vivo, we performed xenograft assay. We found that LINC00173 knockdown significantly decreased the tumor volumes and weight ([Figure 4A](#F0004){ref-type="fig"} and [B](#F0004){ref-type="fig"}). Besides, the Ki67 expression was lower in sh-LINC00173 group than that in control group ([Figure 4C](#F0004){ref-type="fig"}). Moreover, we found that the levels of LINC00173 and PLP2 were still downregulated in sh-LINC00173 group while miR-765 expression was increased ([Figure 4D](#F0004){ref-type="fig"}). Consistently, the protein level of PLC2 was also decreased in sh-LINC00173 group ([Figure 4E](#F0004){ref-type="fig"}). Thus, LINC00173 promotes CRC growth in vivo through miR-765/PLP2 axis.Figure 4LINC00173/miR-765/PLP2 axis affects CRC growth in vivo. (**A**) Tumor volumes were determined every 1 week. (**B**) Tumor weight was measured after 5 weeks post-injection. (**C**) Ki67 expression in tumor tissues was examined by IHC assay. (**D**) Relative expression levels of LINC00173, miR-765 and PLP2 in tumor tissues were analyzed by qRT-PCR. (**E**) Protein level of PLP2 was measured by Western blot. \*\**P*\<0.01.

Discussion {#S0004}
==========

CRC is a common and malignant cancer in gastrointestinal tract. CRC leads to a large number of cancer-related deaths worldwide.[@CIT0013] It is very urgent and important to understand the molecular mechanism of CRC development. Herein, we found that LINC00173 expression was upregulated in CRC tissues and cells. And LINC00173 is a potential prognostic biomarker for CRC patients. We showed that LINC00173 knockdown suppressed the proliferation, migration and invasion of CRC cells in vitro and in vivo. Moreover, we also demonstrated that LINC00173 knockdown sensitized CRC cells to 5-FU treatment. Thus, LINC00173 may be a potential target for CRC therapy.

In recent years, increasing researches have demonstrated that lncRNAs participate in the regulation of tumor development and progression, including CRC.[@CIT0014] For example, lncRNA LINC00483 contributes to growth and invasion of CRC through regulating FMNL2 expression.[@CIT0015] LncRNA kcna3 is a negative regulator of CRC progression via inhibiting YAP11 expression.[@CIT0016] Previously, LINC00173 was reported to promote the proliferation, migration and invasion of lung cancer cells.[@CIT0011] Recently, a study indicates that LINC00173contributes to breast cancer progression.[@CIT0012] However, its roles in CRC are unclear. In our work, LINC00173 silencing repressed growth and metastasis of CRC cells in vitro and in vivo. Moreover, we also revealed that LINC00173 affected the resistance of CRC cells to 5-FU. Our study demonstrated that LINC00173 is a crucial oncogene in CRC.

Subsequently, we identified that miR-765 is a potential target of LINC00173 through bioinformatics, which was confirmed by luciferase reporter assay. MiR-765 may act as anti-tumor roles or oncogenic functions in different cancer cells.[@CIT0017],[@CIT0018] For instance, miR-765 inhibits development of clear cell renal cell cancer via suppressing PLP2 expression.[@CIT0017] MiR-765 accelerates growth of liver cancer cells via inhibiting INPP4B expression.[@CIT0018] Its function in CRC remains to be defined. We performed a lot of assays, such as CCK8 assay, EdU assay and Transwell assay. We found that miR-765 inhibitors reversed the effects of LINC00173 knockdown. Our findings support that miR-765 is a suppressor in CRC.

Afterwards, PLP2 was predicted to be targeted by miR-765. We also used luciferase reporter assay to confirm the interaction between miR-765 and PLP2. Our finding is consistent with a previous report in clear cell renal cell cancer.[@CIT0017] PLP2 has been reported to be involved in several cancers as oncogene.[@CIT0019] For example, PLP2 overexpression promotes the development of cutaneous malignant melanoma.[@CIT0019] PLP2 upregulation promotes proliferation, migration and invasion of glioma.[@CIT0020] Besides, LP2 is also involved in promoting breast cancer cell stemness.[@CIT0021] How it functions in CRC is still elusive. In our study, we showed that PLP2 knockdown suppressed the proliferation, migration and invasion of CRC cells. Our results demonstrated that PLP2 promotes CRC development.

In summary, the current work identified that LINC00173 silencing attenuated growth, metastasis and chemo-resistance of CRC cells through sponging miR-765 from PLP2 mRNA. Our study suggests that LINC00173/miR-765/PLP2 axis may be a potential target for CRC therapy. Nevertheless, there are some limitations in the current study. For instance, more CRC samples are required to determine association between LINC00173 expression and clinical features. Whether LINC00173 could be a diagnostic biomarker is not defined.
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